35th week of 2022 patent applcation highlights part 22 |
Patent application number | Title | Published |
20220274992 | SUBSTITUTED (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL) AMINO COMPOUNDS USEFUL AS JAK 1 INHIBITORS - The disclosure provides compounds and pharmaceutically acceptable salts thereof of Formula (I) The variables, R, R!-R3 and the A-ring are described herein. A can be a cyclohexyl ring. The compounds are inhibitors of JAK1 Kinase and are useful in methods of treating an allergic, inflammatory, or autoimmune orders, in a patient, comprising administering a therapeutically effective amount of compound of Formula I or salt thereof, to the patient. The disclosure also provides pharmaceutical formulations containing a compound of Formula I. | 2022-09-01 |
20220274993 | IRAK4 DEGRADERS AND USES THEREOF - The present invention relates to a method of treating autoimmune/autoinflammatory diseases and hematological malignancies in a subject. | 2022-09-01 |
20220274994 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROP- YRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF - The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease. | 2022-09-01 |
20220274995 | NOVEL METHOD FOR SYNTHESIZING AMANITINS - The invention relates to novel methods for synthesizing amanitin derivatives having an amino group attached to position 6′ of the central tryptophan moiety. The invention furthermore relates to a novel amanitin derivative having an amino group attached to position 6′ of the central tryptophan moiety, novel conjugates of such amanitin derivative, and pharmaceutical compositions comprising such conjugates. | 2022-09-01 |
20220274996 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT - This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of α5-containing GABA | 2022-09-01 |
20220274997 | PIM KINASE INHIBITOR COMPOSITIONS AND USES THEREOF - This disclosure relates to compounds and compositions useful as inhibitors of PIM kinases. Also provided are methods of synthesis and methods of use of PIM inhibitors in treating individuals suffering from cancerous malignancies. | 2022-09-01 |
20220274998 | ELECTROLUMINESCENT DEVICE - Provided is an electroluminescent device. The electroluminescent device includes an anode, a cathode, and an organic layer disposed between the anode and the cathode, wherein the organic layer at least comprises a first compound having a structure of H | 2022-09-01 |
20220274999 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN AND DEPENDANCE DISORDERS - Provided herein are (e.g., controlled release) compositions for the treatment of acute or chronic diseases or disorders. Described herein are processable opioid conjugates. Also described herein are compositions and methods for the treatment of central nervous system (CNS) diseases or disorders including chronic pain (e.g., cancer pain), acute pain, opioid addiction, alcohol addiction, alcohol dependence, opioid-induced constipation, and narcotic depression. Said compositions and methods comprise opioid agonists and/or opioid antagonists, which demonstrate CNS activity and/or other desirable activities. Injection of said compositions subcutaneously or intraspinally provides therapeutic benefit to individuals suffering from CNS diseases or disorders | 2022-09-01 |
20220275000 | NOVEL DIOXOLOISOQUINOLINONE DERIVATIVES AND USE THEREOF - Disclosed are novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts thereof, optical isomers, hydrates, and solvates thereof as well as uses thereof. More specifically, the novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts, optical isomers, hydrates, solvates show inhibition activity of EZH1 (Enhancer of zeste homolog 1) and/or EZH2 (Enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing the compound is also disclosed. | 2022-09-01 |
20220275001 | Benzimidazoles and Methods of Using Same - The present disclosure is concerned with benzimidazole compounds and methods of using these compounds for the treatment of hepatitis (e.g., hepatitis C), RNA virus infections (e.g., Zika virus, dengue virus, Powassan virus, Chikungunya virus, Enterovirus, respiratory syntactical virus (RSV), Rift Valley fever, Influenza virus, Tacaribe virus, Mayaro virus, West Nile virus, yellow fever virus, and coronavirus), and disorders of uncontrolled cellular proliferation (e.g., cancer). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2022-09-01 |
20220275002 | Compounds And Methods For Treating Fibrotic Pathologies - The present application provides methods for treating or preventing diseases and conditions associated with tissue fibrosis. | 2022-09-01 |
20220275003 | ARTEMISININ-DERIVED TRIMERS AND TETRAMERS AND THEIR USE THEREOF - The present disclosure provides compositions comprising artemisinin-derived trimers and tetramers; methods of preparing these compositions; and methods for their use as medicaments. | 2022-09-01 |
20220275004 | MOLECULAR COMPLEXES - The present invention relates to a crystalline molecular complex comprising pinoxaden and a carboxylic acid. The invention also relates to a process for the preparation of the crystalline molecular complex, a herbicidal composition comprising the crystalline molecular complex, and use of the herbicidal composition. | 2022-09-01 |
20220275005 | HETEROCYCLIC COMPOUNDS - The invention provides new heterocyclic compounds having the general formula (I) | 2022-09-01 |
20220275006 | Catalyst Composition and Method for Preparing Isobutene-Based Oligomer Using the Same - The present invention relates to a catalyst composition including an oxonium ion-based catalyst and an aluminum-based cocatalyst, and a method for preparing an isobutene-based polymer using the same. | 2022-09-01 |
20220275007 | FLOW REACTION PROCESS FOR MANUFACTURE OF BORON-CONTAINING AGROCHEMICALS - The present invention relates to methods of preparing benzoxaboroles. Benzoxaborole compounds have shown promise as antimicrobial agents, especially against fungal pathogens. The invention also relates to compositions of acyclic alkoxy boronic acid esters as intermediates, and continuous flow processes of mixing the intermediates with organomagnesium, magnesium, or organolithium reagents to form the desired benzoxaboroles. | 2022-09-01 |
20220275008 | COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY DEVICE - A compound for an organic optoelectronic device, a composition for an organic optoelectronic device including the same, an organic optoelectronic device, and a display device, the compound being represented by Chemical Formula 1: | 2022-09-01 |
20220275009 | CATIONIC GERMANIUM(II) COMPOUNDS, PROCESS FOR PREPARING SAME, AND THEIR USE AS CATALYSTS IN HYDROSILYLATION - A mixture M includes at least one compound A, selected from (a1) a compound of the general formula (I) and/or (a2) a compound of the general formula (I′), at least one compound B, selected from (b1) a compound of the general formula (II) and/or (b2) a compound of the general formula (II′) and/or (b3) a compound of the general formula (II″), and at least one compound C, selected from cationic germanium(II) compounds of the general formula (III). | 2022-09-01 |
20220275010 | NOVEL SILYLCYCLODISILAZANE COMPOUND AND METHOD FOR MANUFACTURING SILICON-CONTAINING THIN FILM USING THE SAME - Provided is a novel silylcyclodisilazane compound, a composition for depositing a silicon-containing thin film containing the same, and a method for manufacturing the silicon-containing thin film using the same, and since the silylcyclodisilazane compound of the present invention has high reactivity, thermal stability and high volatility, it can be used as a silicon-containing precursor, thereby manufacturing a high-quality silicon-containing thin film by various deposition methods. | 2022-09-01 |
20220275011 | CRYSTALLINE FORMS - The invention relates to crystalline forms of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms and their use as a medicament, especially as a P2Y | 2022-09-01 |
20220275012 | Dinuclear Molybdenum Precursors For Deposition Of Molybdenum-Containing Films - Dinuclear molybdenum coordination complexes are described. Methods for depositing molybdenum-containing films on a substrate are described. The substrate is exposed to a dinuclear molybdenum precursor and a reactant to form the molybdenum-containing film (e.g., elemental molybdenum, molybdenum oxide, molybdenum carbide, molybdenum silicide, molybdenum nitride). The exposures can be sequential or simultaneous. | 2022-09-01 |
20220275013 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound including ligand L | 2022-09-01 |
20220275014 | PREPARATION AND APPLICATION OF MIXED-LIGAND NICKEL(II) COMPLEX CONTAINING BISOXAZOLINE-DERIVED NITROGEN HETEROCYCLIC CARBENE LIGAND AND PHOSPHITE LIGAND - The invention discloses a mixed Ni(II) complex containing bisoxazoline-derived nitrogen heterocyclic carbene ligand and phosphite ligand and application thereof; the chemical formula of the mixed Ni(II) complex is Ni(NHC)[P(OR) | 2022-09-01 |
20220275015 | Metallocenes and Methods Thereof - The present disclosure provides metallocene catalyst compounds including at least one —Si— containing linker, catalyst systems including such compounds, and uses thereof. Catalyst compounds of the present disclosure can be hafnium-containing compounds having one or more cyclopentadiene ligand(s) substituted with one or more silyl neopentyl groups and linked with at least one —Si-containing linker. In another class of embodiments, the present disclosure is directed to polymerization processes to produce polyolefin polymers from catalyst systems including one or more olefin polymerization catalysts, at least one activator, and an optional support. | 2022-09-01 |
20220275016 | COMPOUNDS AND METHODS FOR SYNTHESIZING SPHINGOSINES AND GLYCOLIPIDS - The present disclosure is concerned with compounds, compositions, and methods for synthesizing sphingosines and glycolipids including glycosphingolipids, such as but not limited to lactosyl sphingosine. | 2022-09-01 |
20220275017 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF - Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen. | 2022-09-01 |
20220275018 | NOVEL SPIROBICYCLIC INTERMEDIATES - The present invention relates to novel spirobicyclic intermediates useful in the synthesis of spirobicyclic nucleoside analogues. | 2022-09-01 |
20220275019 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION - Compounds useful for forming nucleic acids having the structure of Formula I: | 2022-09-01 |
20220275020 | SALT AND CRYSTAL FORM OF STEROID DERIVATIVE REGULATOR - The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the crystal form, and an application thereof as a GABA | 2022-09-01 |
20220275021 | SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS - Systems and processes for performing solid phase peptide synthesis are generally described. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. In certain embodiments, the inventive systems and methods can be used to perform solid phase peptide synthesis quickly while maintaining high yields. Certain embodiments relate to processes and systems that may be used to heat, transport, and/or mix reagents in ways that reduce the amount of time required to perform solid phase peptide synthesis. | 2022-09-01 |
20220275022 | COMPOSITIONS, KITS AND METHODS USEFUL FOR ANALYZING ANTIBODY-CONTAINING SAMPLES - In some aspects, the present disclosure pertains to sample treatment methods that comprise: contacting an acidic elution solution that is free of primary amine, secondary amine and thiol groups with a sorbent having bound target antibody and separating the elution solution from the sorbent, thereby releasing bound target antibody from the sorbent and forming a first collection fraction that comprises the elution solution and released target antibody; contacting the sorbent with a neutralization buffer solution that is free of primary amine, secondary amine and thiol groups and separating the neutralization buffer solution from the sorbent, thereby forming a second collection fraction that comprises the neutralization buffer solution; and forming a neutralized solution that comprises the first collection fraction and the second collection fraction. In other aspects, the present disclosure pertains to kits for performing such sample treatment methods. | 2022-09-01 |
20220275023 | PRODUCTION OF PROTEIN SOLID MATERIAL - This method for producing a protein crystal includes: a step (a) for adding, to a protein synthesis system, a nucleic acid that encodes crystalline protein; and a step (b) for incubating the protein synthesis system during the predetermined time until the crystalline protein encoded by the added nucleic acid is expressed and the expressed crystalline protein completes the formation of crystals, wherein the protein synthesis system is a cell-free protein synthesis system. | 2022-09-01 |
20220275024 | Process for Purifying Monoclocal Antibodies - A process for purifying a liquid feedstock comprising a monoclonal antibody and impurities, the process comprising passing the liquid feedstock through an apparatus comprising at least two processing units, each such unit producing a product stream containing purified monoclonal antibody and optionally a waste stream comprising at least some of the impurities, wherein each unit comprises specified components (i) to (v) which include a multiple inlet flow-controller comprising two or more variable flow inlet valves for in situ production of a bioprocessing liquid by combining at least two liquids in a desired ratio. One of the units performs chromatography and another performs viral inactivation. The units may be essentially the same except for a device they contain, leading to advantages in terms of simplicity, cost and ease of operation, lower risk of operator error, easier maintenance and lower inventory of spare parts. | 2022-09-01 |
20220275025 | BONE REMODELING REGULATORY PEPTIDES AND APPLICATION THEREOF - A series of bone remodeling regulatory peptides and application thereof are disclosed. Through sequence alignment, structure analysis, physical and chemical properties and function prediction, a series of bone remodeling regulatory peptides are designed and synthesized by solid-phase peptide synthesis method:
| 2022-09-01 |
20220275026 | IL-2RBETA BINDING COMPOUNDS - IL-2Rβ ligands and IL-2Rγc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2Rβ ligands and/or the IL-2Rγc ligands can be IL-2 receptor agonists. | 2022-09-01 |
20220275027 | ATYPICAL SPLIT INTEINS AND USES THEREOF - The present disclosure relates to atypical split N- and C-inteins and variants thereof. This disclosure also relates to complexes comprising the split N- or C-inteins of this disclosure and a compound of interest and compositions comprising said complexes. In addition, this disclosure relates to methods of using the atypical split N- and C-inteins. | 2022-09-01 |
20220275028 | Systems, Methods And Compositions For Recombinant In Vitro Transcription And Translation Utilizing Thermophilic Proteins - Another aim of the current invention may include a recombinant cell-free expression system, the reaction mixture containing all the cell-free reaction components necessary for the in vitro biosynthesis of biological compounds, proteins, enzymes, biosimilars or chemical modification of small molecules. | 2022-09-01 |
20220275029 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY - The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell. | 2022-09-01 |
20220275030 | DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS - The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections. | 2022-09-01 |
20220275031 | SYNTHETIC NUCLEOTIDE SEQUENCES ENCODING INSECTICIDAL CRYSTAL PROTEIN AND USES THEREOF - The present disclosure provides codon optimized synthetic nucleotide sequences encoding | 2022-09-01 |
20220275032 | HSP Fusion Protein with Anti-Chemorepellant Agent for Treatment of Cancer - This disclosure is directed to immune treatment of a disease (e.g., cancer) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain. | 2022-09-01 |
20220275033 | MODIFIED CYANOBACTERIUM, MODIFIED CYANOBACTERIUM PRODUCTION METHOD, AND PROTEIN PRODUCTION METHOD - A modified cyanobacterium in which an organic channel protein which improves protein permeability of an outer wall is expressed. | 2022-09-01 |
20220275034 | ADENOVIRAL CHIMERIC TDP-43 PROTEINS - An adenovirus or adenoviral vector is described that includes a non-native nucleotide sequence capable of expressing a chimeric protein comprising an N-terminal nucleotide binding domain of transactivation response element DNA-binding protein (TDP-43), a C-terminal domain derived from a splicing repressor, and an autoregulatory element. Methods of using the adenovirus or adenoviral vector to treat degenerative diseases such as inclusion body myocytosis, amyotrophic lateral sclerosis, and frontotemporal dementia are also described. | 2022-09-01 |
20220275035 | FCRN ANTAGONISTS AND METHODS OF USE - Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions. | 2022-09-01 |
20220275036 | Modified BCL9 Mimetic Peptides - Provided are BCL9 mimetic peptides having a modified a-helical homology domain-2 (HD2) region and, optionally, a cell-penetrating region, compositions comprising the BCL9 mimetic peptides, and methods of inhibiting proliferation of and/or promoting cytotoxicity in a neoplastic cell using the BCL9 mimetic peptides. | 2022-09-01 |
20220275037 | -AMYLOID CYCLIC RIBONUCLEIC ACID, POLYPEPTIDE, AND APPLICATION THEREOF - The invention discloses a β-amyloid cyclic ribonucleic acid, a polypeptide and an application thereof. The present invention finds that the APP gene can generate a variety of circular RNAs from the AP coding region through reverse splicing, which is named β-amyloid circular ribonucleic acid circAβ. With the help of the newly established circular RNA research method, a variety of peptides produced by circAβ were identified, and such peptides could be further processed to form Aβ, which in turn formed β-amyloid plaques in primary neuronal cultures, reflecting key hallmarks of AD neuropathology. circAβ and its translated proteins represent novel targets in AD therapy. | 2022-09-01 |
20220275038 | CLSP DERIVATIVE INCAPABLE OF BEING AFFECTED BY CLSP INHIBITING SUBSTANCE, AND CLSP ACTIVITY ENHANCING/PROTECTING AGENT - [Problem] Provided is a calmodulin-like skin protein (CLSP) derivative, which has an activity to suppress neuronal cell dysfunction or cell death associated with e.g., Alzheitner's disease stronger than of humanin, and which is insensitive to an inhibitory action by an inhibitor of the activity; a polypeptide which has an action/activity to potentiate or protect the Alzheimer's disease-suppressing activity by CLSP; and the like. | 2022-09-01 |
20220275039 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 - The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders. | 2022-09-01 |
20220275040 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 - The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders. | 2022-09-01 |
20220275041 | MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY AND THEIR USES - Non-human IFNL3 polypeptides and their uses thereof are provided. Exemplary embodiments provide IFNL3 polypeptides which include one or more amino acid substitutions, additions, or deletions with natural or non-naturally encoded amino acids, and/or linkage or fusion to other biologically active molecules including other IFNL3 polypeptides, as well as PK enhancing moieties (PKEMs). Additionally, use of said IFNL3 polypeptides for innate immune system stimulation, as a vaccine adjuvant, as well as treatment or prevention of diseases such as viral and bacterial infections, and inflammation, is also provided. | 2022-09-01 |
20220275042 | RELAXIN ANALOGS AND METHODS OF USING THE SAME - Relaxin (RLN) analogs are disclosed including modifications that increase half-life when compared to native, human RLN, that maintain selectivity to the RXFP1 receptor and that provide in vitro and in vivo stability for improved druggability properties and less immunogenicity. Pharmaceutical compositions also are disclosed that include one or more of the RLN analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the RLN analogs also are disclosed, especially for treating cardiovascular, pulmonary and/or renal conditions, diseases or disorders. | 2022-09-01 |
20220275043 | SOLUBLE MULTIMERIC IMMUNOGLOBULIN-SCAFFOLD BASED FUSION PROTEINS AND USES THEREOF - The present disclosure provides soluble, multimeric fusion proteins that bind to a component of the MHC/TCR immune complex, wherein the fusion proteins comprise a soluble T cell receptor (TCR) or soluble Major Histocompatibility Complex (MHC) linked to an immunoglobulin framework by a multimerization domain. The disclosure also features compositions and methods of using the same for therapeutic or diagnostic use. | 2022-09-01 |
20220275044 | T CELL RECEPTOR FOR RECOGNIZING SSX2 ANTIGEN SHORT PEPTIDE - The present invention provides a T cell receptor (TCR) capable of specifically binding a short peptide KASEKIFYV derived from an SSX2 antigen. The antigen short peptide KASEKIFYV can form a complex with HLA A0201 and be presented together to a cell surface. The present invention further provides a nucleic acid molecule encoding the TCR and a vector comprising the nucleic acid molecule. In addition, the invention further provides a cell that transduces the TCR of the present invention. | 2022-09-01 |
20220275045 | HIGH AFFINITY T-CELL RECEPTOR CAPABLE OF IDENTIFYING NY-ESO-1 ANTIGEN - Provided is a T-cell receptor (TCR) having the characteristic of binding a SLLMWITQC-HLA A0201 complex. The binding affinity to the SLLMWITQC-HLA A0201 complex is at least 2 times that of a wild-type TCR to the SLLMWITQC-HLA A0201 complex. The TCR may be used alone or in combination with a therapeutic agent, so as to target a tumor cell presenting the SLLMWITQC-HLA A0201 complex. | 2022-09-01 |
20220275046 | T CELL RECEPTORS AND METHODS OF USE THEREOF - The present disclosure is directed recombinant T cell receptors capable of binding a MAGE-A2 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof. | 2022-09-01 |
20220275047 | T CELL RECEPTORS AND METHODS OF USE THEREOF - The present disclosure is directed recombinant T cell receptors capable of binding a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof. | 2022-09-01 |
20220275048 | DIMER IMMUNOADHESIN, PHARMACEUTICAL COMPOSTION AND USE THEREOF - A soluble dimeric immunoadhesin includes a dimerized first polypeptide chain and a dimerized second polypeptide chain. The first polypeptide chain has a general formula of Z1-Z2, and the second polypeptide chain has a general formula of Y1-Y2. Z1 is (i) an extracellular domain of a first cell surface receptor or a functional variant or fragment thereof, or (ii) a first cytokine or a functional variant or fragment thereof; Z2 is a dimerization domain of an immunoglobulin constant region or a functional variant or fragment thereof. Y1 is an extracellular domain of a second cell surface receptor or a functional variant or fragment thereof, or (ii) a second cytokine or a functional variant or fragment thereof. Y2 is a dimerization domain of an immunoglobulin constant region or a functional variant or fragment thereof. A dimeric protein can be used for the treatment and prevention of infertility-related diseases. | 2022-09-01 |
20220275049 | ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF - Provided are novel antigenic polypeptides comprising tumor-associated peptides, and compositions comprising the same. Such antigenic polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using such polypeptides and compositions, methods of treating a disease using such polypeptides and compositions, kits comprising such polypeptides and compositions, and methods of making such compositions. | 2022-09-01 |
20220275050 | HIGH YIELD PRODUCTION AND USE OF ENZYMATIC-EXCHANGEABLE PEPTIDE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I SINGLE CHAIN TRIMER TETRAMER - The present invention relates to methods to produce an enzymatic-exchangeable peptide Major Histocompatibility Complex Class I (MHC-I) Single Chain Trimer (SCT), or tetramer thereof, constructs encoding same and uses thereof, such as detection or isolation of antigen-specific CD8 | 2022-09-01 |
20220275051 | MHC CLASS II MOLECULES AND METHODS OF USE THEREOF - The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DQ beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof. | 2022-09-01 |
20220275052 | RECEPTOR - The present invention provides a chimeric receptor which comprises: a ligand-binding exodomain; and an endodomain which comprises: (i) a cytokine receptor endodomain; and (ii) an intracellular T cell signalling domain. | 2022-09-01 |
20220275053 | MODIFIED MULTIMERIC BICYCLIC PEPTIDE LIGANDS - The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold, characterised in that said multimeric binding complex additionally comprises a modifier group conjugated thereto. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said multimeric binding complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said multimeric binding complexes and drug conjugates and to the use of said multimeric binding complexes and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137 and to the use in an analytical method (i.e. as a tracer or a tag). | 2022-09-01 |
20220275054 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME - The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions. | 2022-09-01 |
20220275055 | DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS - Provided is a drug target for idiopathic pulmonary fibrosis, and the use thereof. The drug target is AREG signaling in AT2 cells of the lung. The drug target can be used to screen drugs for treating and/or preventing pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) of animals and human beings. | 2022-09-01 |
20220275056 | SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR COMPOSITIONS - A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. | 2022-09-01 |
20220275057 | FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF - The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D′ domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins. | 2022-09-01 |
20220275058 | PURIFICATION OF FACTOR VIII SUBSPECIES - The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies. | 2022-09-01 |
20220275059 | ANTIBODIES - The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection. | 2022-09-01 |
20220275060 | ANTI-PRE-S1 HBV ANTIBODIES - Provided are human antibodies that specifically bind to HBV Pre-S1 domain ligand and inhibit HBV or HDV infection, antibodies binding to a set of amino acid residues that are critical for viral receptor engagement, and uses of these antibodies to prevent, or treat or diagnose HBV or HDV infection. | 2022-09-01 |
20220275061 | THERAPEUTIC PROTEIN FORMULATIONS COMPRISING ANTIBODIES AND USES THEREOF - The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-influenza antibodies or antigen-binding fragments thereof in an amount ranging from 30 to 150 mg/mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization. Methods of generating an aerosol and treating influenza are also provided. | 2022-09-01 |
20220275062 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA - A p38 MAPK inhibitor for use in the treatment or prevention of severe influenza in a human patient. In some embodiments, the severe influenza may be characterised by hypercytokinemia involving elevated levels of one or more pro-inflammatory cytokines. The p38 MAP kinase inhibitor may act to inhibit the release of such pro-inflammatory mediators from endothelial cells. In some embodiments, the p38 MAP kinase inhibitor may inhibit the release of IP 10 from endothelial cells, preferably in a dose-dependent manner. | 2022-09-01 |
20220275063 | ANTI-CHIKV ANTIBODIES AND USES THEREOF - The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease. | 2022-09-01 |
20220275064 | ANTIBODY COMPOSITIONS FOR DISRUPTING BIOFILMS - Provided herein are methods and compositions for disrupting bio films in vitro and in vivo. Also disclosed are antibodies comprising a specified heavy chain (HC) immunoglobulin variable domain sequence and/or a specified light chain (LC) immunoglobulin variable domain sequence. | 2022-09-01 |
20220275065 | MULTIVALENT DNA ANTIBODY CONSTRUCTS AND USE THEREOF - Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including a recombinant nucleic acid sequence that encodes an antibody, a synthetic antibody, or a synthetic multivalent antibody to a subject. The disclosure also provides compositions and methods of preventing and/or treating a bacterial infection in a subject using said antibody, synthetic antibody, or synthetic multivalent antibody. | 2022-09-01 |
20220275066 | SINGLE DOMAIN ANTIBODIES BINDING TO TETANUS NEUROTOXIN - The present invention relates to single domain antibodies (SDAs) that are capable of binding to tetanus neurotoxin. The invention further relates to polypeptide constructs comprising such an SDA as well as an SDA that is capable of binding to a serum protein, preferably to serum albumin or immunoglobulin. The invention also relates to nucleic acids encoding such SDAs or polypeptide constructs, to pharmaceutical compositions comprising such SDAs or polypeptide constructs, the medical use thereof and to their use in the treatment of tetanus. | 2022-09-01 |
20220275067 | ANTIBODIES RECOGNIZING TAU - The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration. | 2022-09-01 |
20220275068 | COMPOSITIONS AND METHODS OF USING A HUMANIZED ANTI-DKK2 ANTIBODY - The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8 | 2022-09-01 |
20220275069 | BINDING AGENTS AND USES THEREOF - The present invention relates to inhibitors that bind to gasdermin D and inhibit gasdermin D-mediated cell death and inflammation. The inhibitors can be proteinaceous, for example antigen binding proteins or non-proteinaceous, such as aptamers. It is disclosed an antibody that binds to the peptide of SEQ ID NO: 9: KREGSGRFSLPGATC. In one embodiment the inhibitor binds to gasdermin D and inhibits its association with lipids, such as wherein the inhibitor binds to gasdermin D and neutralizes the association of gasdermin D with lipids, optionally wherein the inhibitor binds to gasdermin D and inhibits its association with phosphatidyl inositol 4-phosphate and/or phosphatidyl inositol 4,5-bisphosphate, such as wherein the inhibitor binds to gasdermin D and neutralizes the association of gasdermin D with phosphatidylinositol 4-phosphate and/or phosphatidyl inositol 4,5-bisphosphate. | 2022-09-01 |
20220275070 | DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF C5-RELATED DISEASES BY THE USE OF THE ANTI-C5 ANTIBODY CROVALIMAB - The present invention relates to a dosage and administration regimen of anti-C5 antibodies, particularly of the anti-C5 antibody Crovalimab, for use in a method of treating or preventing C5-related disease in a subject, including paroxysmal nocturnal hemoglobinuria (PNH). The dosage and treatment regimen of the present invention include the administration of an anti-C5 antibody, preferably of the anti-C5 antibody Crovalimab, with loading doses followed by the administration of (a) maintenance dose(s) of the anti-C5 antibody to the subject, wherein the initial administered loading dose is intravenously given to the subject and the remaining loading and maintenance doses are subcutaneously administered in a lower dosage as the intravenously administered loading dose. | 2022-09-01 |
20220275071 | DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF C5-RELATED DISEASES BY THE USE OF THE ANTI-C5 ANTIBODY CROVALIMAB - The present invention relates to a dosage and administration regimen of anti-C5 antibodies, particularly of the anti-C5 antibody Crovalimab, for use in a method of treating or preventing C5-related disease in a subject, including paroxysmal nocturnal hemoglobinuria (PNH). The dosage and treatment regimen of the present invention include the administration of an anti-C5 antibody, preferably of the anti-C5 antibody Crovalimab, with loading doses followed by the administration of (a) maintenance dose(s) of the anti-C5 antibody to the subject, wherein the initial administered loading dose is intravenously given to the subject and the remaining loading and maintenance doses are subcutaneously administered in a lower dosage as the intravenously administered loading dose. | 2022-09-01 |
20220275072 | ANTIBODIES THAT BIND TO PATHOLOGICAL TAU SPECIES AND USES THEREOF - The present disclosure relates to antibodies that bind selectively to pathological Tau, including compositions and methods relating to such antibodies, such as for treating tauopathies, neurodegenerative diseases associated with pathological aggregation of Tau. | 2022-09-01 |
20220275073 | Anti-Sclerostin Antibody Formulations - The present disclosure is directed to pharmaceutical compositions comprising an anti-sclerostin antibody. | 2022-09-01 |
20220275074 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF - The present invention relates to multifunctional protein molecules comprising decorin and uses thereof. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody and methods of their production and uses thereof. | 2022-09-01 |
20220275075 | METHODS AND COMPOSITIONS FOR PDGF-CC INHIBITION - The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of platelet derived growth factor C (PDGF-C). Such antibodies may be used for the modulation of PDGF-C activity in or secreted from a cell to study its effects on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with PDGF-C signing pathway. | 2022-09-01 |
20220275076 | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE - The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease. Anti-myostatin antibodies of the present invention may be for use in increasing mass of muscle tissue. Anti-myostatin antibodies of the present invention may be for use in increasing strength of muscle tissue. | 2022-09-01 |
20220275077 | IL-38-SPECIFIC ANTIBODIES - This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof. The antibodies, or antigen-binding fragments thereof, described here partially or fully block, inhibit, or neutralize a biological activity of IL 38. Methods described here relate to inhibiting tumor growth or metastasis in an individual afflicted by tumor growth and/or metastasis. | 2022-09-01 |
20220275079 | Clonal Hematopoiesis and Risk of Chronic Liver Disease - This application provides for methods of treatment for liver disease, especially in subjects with a DNMT3A, TET2, JAK2, and/or ASXL1. The application also provides for methods of diagnosing liver disease, as well as kits for use in the claimed methods. | 2022-09-01 |
20220275080 | BINDING MOLECULE SPECIFIC TO LRIG-1 PROTEIN, AND USE THEREOF - Provided herein is a binding molecule capable of specifically binding to LRIG-1 protein, which is located on the surface of a regulatory T cell. Also provided is pharmaceutical composition comprising the binding molecule. Further provided are methods of treating an immune-related disease using the binding molecule or pharmaceutical composition disclosed herein. | 2022-09-01 |
20220275081 | BINDING MOLECULE SPECIFIC FOR LRIG-1 PROTEIN AND USE THEREOF - Provided herein is a binding molecule capable of specifically binding to LRIG-1 protein, which is located on the surface of a regulatory T cell. Also provided is pharmaceutical composition comprising the binding molecule. Further provided are methods of treating a cancer using the binding molecule or pharmaceutical composition disclosed herein. | 2022-09-01 |
20220275082 | Covalent Diabodies and Uses Thereof - The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule. | 2022-09-01 |
20220275083 | Bispecific Epitope Binding Protein Comprising Anti-4-1BB Antibody and a PD-1 Protein or Fragments Thereof and Use Thereof - The present invention provides a bispecific epitope binding protein comprising an anti-4-1BB agonist antibody and a PD-1 protein or a fragment thereof that binds to PD-L1 with high affinity. The bispecific epitope binding protein simultaneously and independently binds to 4-1BB and PD-L1, which engage 4-1BB upregulated T cells, especially effector CD8+ T cells, with tumor cells expressing PD-L1. These interactions induce strong activation of the cytotoxic activity of anti-tumor effector CD8+ T cells by both blocking PD-1/PD-L1-mediated inhibitory signaling and activating 4-1BB-mediated costimulatory signaling in mouse models. This bispecific epitope binding protein has a much stronger oncolytic effect compared to each component alone. | 2022-09-01 |
20220275084 | ANTIFIBROTIC ACTIVITY OF CD47 BLOCKADE - Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition. | 2022-09-01 |
20220275085 | MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS - Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets. | 2022-09-01 |
20220275086 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY - Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce. | 2022-09-01 |
20220275087 | PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES - The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease. | 2022-09-01 |
20220275088 | ANTIBODIES AGAINST PD-1 AND METHODS OF USE THEREOF - The present invention is directed to human monoclonal antibodies that bind to the cell-surface receptor, PD-1 (programmed death 1). The antibodies can be used to treat cancer and chronic viral infections. | 2022-09-01 |
20220275089 | ANTI-CTLA4-ANTI-PD-1 BISPECIFIC ANTIBODY AND USES THEREOF - The present invention relates to the field of tumor treatment and molecular immunology, and particularly, to an anti-CTLA4/anti-PD-1 bispecific antibody and use thereof. Specifically, the anti-CTLA4/anti-PD-1 bifunctional antibody comprises a first protein functional region targeting PD-1 and a second protein functional region targeting CTLA4, wherein, according to the EU numbering system, the heavy chain constant region of the immunoglobulin comprised in the bispecific antibody has mutations at any 2 or 3 of positions 234, 235 and 237, and the affinity constant of the bispecific antibody to FcγRIIIa and/or C1q is reduced after the mutation as compared to that before the mutation. The bifunctional antibody of the present invention can well and specifically bind to CTLA4 and PD-1, specifically relieve immunosuppression of CTLA4 and PD-1 in an organism, and activate T lymphocytes, thus having good application prospect. | 2022-09-01 |
20220275090 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors - This invention relates to a methods and compositions for treating a disease by administering a combination therapy comprising an anti-CD38 antibody and a poly ADP ribose polymerase inhibitor (PARPi); an anti-CD38 antibody and an adenosine receptor antagonist; or an anti-CD38 antibody, a PARPi and an adenosine receptor antagonist, to a subject (e.g., a human patient) in need thereof. | 2022-09-01 |
20220275091 | COMBINATION OF TIM-4 ANTAGONIST AND PD-1 ANTAGONIST AND METHODS OF USE - Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist (e.g., an antibody) in combination with a TIM-4 antagonist (e.g., an antibody). | 2022-09-01 |
20220275092 | DOSAGE REGIMES FOR THE ADMINISTRATION OF A LAG-3/PD-L1 BISPECIFIC ANTIBODY - The application relates to dosage regimes for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients. | 2022-09-01 |